Biotech Catches Major Premarket Bid

Biotech Catches Major Premarket Bid

Biotech Catches Major Premarket Bid By: Tomas Ronolski - News

Tuesday, September 19, 2023

A Boston-based biotech company is capturing the collective attention of the trading community after it was announced that Truist Securities initiated coverage on the stock, giving it a buy rating and a price target of $10.00/share.

Seeing that shares of Praxis Precision Medicines Inc. (Nasdaq:PRAX) closed at just $1.42/share on Monday, it’s no wonder that traders are excited before Tuesday’s opening bell. Shares are currently bid up at $1.54/share (+8.45% implied open for sellers) at the time of writing. It should be an exciting session for this small cap!

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Copyright © 2023 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares on a Tear After Interception of Multiple Drill Shows Promise for Lithium
Momentum Continues To Build For This Micro Cap In The Tech Space
Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher
Most Popular

Back to Top